US company Nanomedical Diagnostics has worked with MEMS foundry Rogue Valley Microdevices to deliver what is said to be the first mass produced graphene based biosensor.
Called the AGILE R100, the benchtop device is designed to provide biophysical data to pharmaceutical and biotherapeutics companies seeking more informed decisions earlier in the drug discovery process.
“Rogue Valley Microdevices has been a true partner in developing a viable large-scale fabrication process for our AGILE biosensor chips,” said Nanomedical Diagnostics’ CEO Ross Bundy. “The ability to manufacture graphene biosensors at scale will enable us to create significant cost reductions for many life science and healthcare applications, as well as introduce game-changing capabilities that have never been seen before.”
The graphene biosensor supports Nanomedical’s Field Effect Biosensing (FEB) technology. FEB is an electrical technique which measures the current across the biosensor in which targets are immobilised. Any interaction or binding that occurs on the surface causes a change in conductance that is monitored in real-time, enabling accurate kinetic, affinity and concentration measurements.
Author
Graham Pitcher
Source: www.newelectronics.co.uk